Top of the morning to you. We have just returned from one of the local schoolhouses, where we have deposited a sleepy short person. Nonetheless, we are here in time to provide the usual headlines before we gear up for the rest of the day. Meetings and deadlines - and lots of documents - are in store. We know you can relate. So please join us for a cup of mandatory stimulation as we begin the journey. Hope your day goes well and stay in touch...
FDA OKs Early Submission For Vivus Diet Pill (Reuters)
J&J Faces Arkansas Trial Over Risperdal Marketing (Bloomberg News)
Elan Adds New Directors After Sustained Pressure (Reuters)
Abbott Cuts 160 Jobs, Mostly At California Plant (Chicago Tribune)
Longer Supply May Help Women Stick With 'The Pill' (Reuters)
Express Scripts Sues Walgreen Over Medicare Drug Plan (Bloomberg News)
Pfizer CFO Says No Decision Yet On Divestments (Pharma Times)
Another Heparin-Like Crisis Is Inevitable:FDA (Bloomberg News)
Vaccine Injury Case Thrown Out (Courthouse News Service)
Merck Puts Faith In Hep C And C. Difficile Drugs (Reuters)
Glaxo Pushes Reps As Educators, Not Salespeople (MedCity News)
EDITOR'S NOTE: Please check this post for updates throughout the morning